Logo image of IOBT

IO BIOTECH INC (IOBT) Stock Fundamental Analysis

NASDAQ:IOBT - Nasdaq - US4497781090 - Common Stock - Currency: USD

1  +0.01 (+1.01%)

Fundamental Rating

2

IOBT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 562 industry peers in the Biotechnology industry. While IOBT seems to be doing ok healthwise, there are quite some concerns on its profitability. IOBT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IOBT has reported negative net income.
IOBT had a negative operating cash flow in the past year.
IOBT had negative earnings in each of the past 5 years.
IOBT had a negative operating cash flow in each of the past 5 years.
IOBT Yearly Net Income VS EBIT VS OCF VS FCFIOBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

IOBT has a Return On Assets of -141.05%. This is amonst the worse of the industry: IOBT underperforms 83.51% of its industry peers.
With a Return On Equity value of -203.11%, IOBT is not doing good in the industry: 69.50% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -141.05%
ROE -203.11%
ROIC N/A
ROA(3y)-45.97%
ROA(5y)-105.42%
ROE(3y)-50.49%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IOBT Yearly ROA, ROE, ROICIOBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600 800

1.3 Margins

IOBT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IOBT Yearly Profit, Operating, Gross MarginsIOBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, IOBT has about the same amount of shares outstanding.
IOBT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for IOBT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IOBT Yearly Shares OutstandingIOBT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
IOBT Yearly Total Debt VS Total AssetsIOBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -9.35, we must say that IOBT is in the distress zone and has some risk of bankruptcy.
IOBT has a worse Altman-Z score (-9.35) than 73.23% of its industry peers.
There is no outstanding debt for IOBT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.35
ROIC/WACCN/A
WACCN/A
IOBT Yearly LT Debt VS Equity VS FCFIOBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

IOBT has a Current Ratio of 3.33. This indicates that IOBT is financially healthy and has no problem in meeting its short term obligations.
IOBT's Current ratio of 3.33 is on the low side compared to the rest of the industry. IOBT is outperformed by 61.52% of its industry peers.
A Quick Ratio of 3.33 indicates that IOBT has no problem at all paying its short term obligations.
With a Quick ratio value of 3.33, IOBT perfoms like the industry average, outperforming 41.13% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.33
Quick Ratio 3.33
IOBT Yearly Current Assets VS Current LiabilitesIOBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.87% over the past year.
EPS 1Y (TTM)32.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, IOBT will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.35% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.36%
EPS Next 2Y9.97%
EPS Next 3Y14.04%
EPS Next 5Y19.35%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IOBT Yearly Revenue VS EstimatesIOBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
IOBT Yearly EPS VS EstimatesIOBT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IOBT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IOBT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IOBT Price Earnings VS Forward Price EarningsIOBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IOBT Per share dataIOBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as IOBT's earnings are expected to grow with 14.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.97%
EPS Next 3Y14.04%

More info and screens

0

5. Dividend

5.1 Amount

IOBT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IO BIOTECH INC

NASDAQ:IOBT (5/9/2025, 8:01:12 PM)

1

+0.01 (+1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)05-19 2025-05-19/bmo
Inst Owners67.38%
Inst Owner Change-0.39%
Ins Owners0.34%
Ins Owner Change0.27%
Market Cap65.88M
Analysts78.33
Price Target9.18 (818%)
Short Float %0.17%
Short Ratio0.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.71%
Min EPS beat(2)-22.76%
Max EPS beat(2)-20.66%
EPS beat(4)2
Avg EPS beat(4)-2.99%
Min EPS beat(4)-22.76%
Max EPS beat(4)18.3%
EPS beat(8)4
Avg EPS beat(8)0.01%
EPS beat(12)7
Avg EPS beat(12)1.62%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.4
P/tB 1.4
EV/EBITDA N/A
EPS(TTM)-1.45
EYN/A
EPS(NY)-1.42
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.09
OCFYN/A
SpS0
BVpS0.71
TBVpS0.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -141.05%
ROE -203.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.97%
ROA(5y)-105.42%
ROE(3y)-50.49%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 150.23%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.33
Quick Ratio 3.33
Altman-Z -9.35
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next Y2.36%
EPS Next 2Y9.97%
EPS Next 3Y14.04%
EPS Next 5Y19.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.82%
EBIT Next 3Y-12.25%
EBIT Next 5YN/A
FCF growth 1Y-19.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.1%
OCF growth 3YN/A
OCF growth 5YN/A